In cholangiocarcinoma, NTRK1-3 fusions are estimated to occur in about 3.6% of cases, particularly intrahepatic subtypes, and represent one of the few actionable alterations beyond FGFR2 fusions and IDH1 mutations [121,122]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.